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A B S T R A C T
This study examined the association between
transforming growth factor (TGF)-b1 polymor-
phisms and brucellosis. The TGF-b1 genotypes at
codons 10 and 25 were determined by an amplifi-
cation refractory mutation system-PCR among 425
brucellosis patients and 213 healthy volunteers.
The frequencies of TGF-b1 codons 10 C and 25 G
were significantly higher among patients than
among controls, as was that of TGF-b1 codon
10 C ⁄C.Thehigh-producerhaplotype(CG ⁄TG)was
more frequent among patients than among con-
trols. The findings suggest that genetic polymorph-
ism in codons 10 and 25 of the TGF-b1 gene might
contribute to the development of brucellosis.
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Brucella spp. are Gram-negative, facultative, intra-
cellular bacteria that cause the chronic zoonotic
disease known as brucellosis. Genetic polymor-
phisms affecting the production levels of certain
cytokines may be important determinants of risk,
severity and ⁄ or protection for some infectious
diseases [1]. Two single nucleotide polymor-
phisms have been identified in the DNA sequence
encoding the signal sequence of the transforming
growth factor (TGF)-b1 cytokine, located at posi-
tions +869 and +915, that result, respectively, in
variations of codons 10 (Leu to Pro) or 25 (Arg to
Pro) [2]. Both single-base substitutions result in
different levels of TGF-b1 production, and three
different cytokine-producer types have been dis-
tinguished [3,4]. Although the immunogenetic
aspects of chronic intracellular infections have
been studied extensively, little is known about the
host’s genetic influence on human brucellosis.
The present case-control study was designed to
assess the association between single nucleotide
polymorphisms of T+869C and G+915C at exon 1
of the TGF-b1 gene and susceptibility to brucel-
losis, and to identify any haplotypes associated
with predisposition to brucellosis.
In total, 425 (206 male and 219 female) brucel-
losis patients referred to Sina Hospital, Hamadan
Province, Iran and 213 (184 male and 29 female)
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healthy volunteers were recruited between March
2003 and August 2005. A diagnosis of brucellosis
was established on the basis of clinical, bacterio-
logical, serological and epidemiological findings.
The healthy volunteers were matched for gender,
age, geographical area and epidemiological con-
ditions, and were negative for anti-Brucella anti-
body. Informed consent was obtained from each
individual, and the Ethics Committee of Hama-
dan University Hospital approved the study
protocol.
Genomic DNA was extracted from EDTA-trea-
ted peripheral blood by a standard method and
the samples were genotyped using an amplifica-
tion refractory mutation system-PCR, as described
previously [5]. Frequencies of allele and genotype
distribution were analysed using the chi-square
test, and ORs with 95% CIs were calculated for
disease susceptibility in carriers of specific alleles.
The genotype frequencies of all polymorphisms
were in accordance with the Hardy–Weinberg
equilibrium (data not shown). The frequency of
the C allele was higher among patients than
among controls (72.7% vs. 43.9%, p < 0.0001)
(Table 1), but the TGF-b1 codon 10 T and codon
25 C alleles were less common among patients
than among controls (27.3% vs. 56.1%, p <0.0001,
and 25.3% vs. 31.5%, p 0.001, respectively).
Interestingly, the mutant G allele at codon 25
was more prevalent among patients than among
controls (74.7% vs. 61.5%, p 0.02). The prevalence
of TGF-b1 codon 10 C ⁄C and codon 10 C ⁄T was
also higher among patients than among controls
(52% vs. 29.9%, and 41.4% vs. 29.6%, p <0.0001,
respectively), while homozygous mutant codon 10
was less common among patients than among
controls (6.6% vs. 41.3%, p <0.0001) (Table 1).
These findings suggest that the TGF-b1 codon
10 T ⁄T genotype may serve as a protective factor
for the disease (OR 0.38, 95% CI 0.27–0.54;
p <0.001), whereas the codon 10 C ⁄C and
25 G ⁄G genotypes may be potential risk-factors
for brucellosis (OR 9.98, 95% CI 6.24–15.98,
p <0.001, and OR 1.6, 95% CI 1.1–2.42, respec-
tively).
The results of the haplotype analysis are shown
in Table 2. The TGF-b1 high-producer haplotype
CG ⁄TG was more frequent among patients than
among controls (p 0.004), while the other high-
producer haplotype TG ⁄TG was less frequent
among patients than among controls. Intermedi-
ate producers were more prevalent among pa-
tients, while low-producer genotypes were more
frequent among controls. None of the patients
had the CC ⁄TG haplotype, which was frequent
among the controls. Generally, there was a pat-
tern of high production of TGF-b1 among patients
with brucellosis.
Table 1. Distributions of allele and genotype frequencies
of transforming growth factor (TGF)-b1 codons 10 and 25
among brucellosis patients and healthy subjects
TGF-b1 polymorphism
Brucellosis patients
n = 425
Controls
n = 213 p
Codon 10, n (%)
C allele 618 (72.7) 187 (43.9) <0.0001
T allele 232 (27.3) 239 (56.1) <0.0001
Genotype, n (%)
C ⁄C 221 (52) 62 (29.1)
C ⁄T 176 (41.4) 63 (29.6) <0.0001
T ⁄T 28 (6.6) 88 (41.3)
Codon 25, n (%)
C allele 215 (25.3) 164 (31.5) 0.001
G allele 635 (74.7) 262 (61.5) 0.02
Genotype, n (%)
C ⁄C 77 (18.1) 49 (23)
C ⁄G 61 (14.4) 66 (31) <0.0001
G ⁄G 287 (67.5) 98 (46)
Numbers in parentheses indicate frequencies (%).
Table 2. Estimate of pairwise haplotype frequencies of transforming growth factor (TGF)-b1 among brucellosis and
control subjects
TGF-b1 Haplotype Genotypea
Brucellosis patients Healthy controls
p TGF-b1n (%)
Frequency
2n = 425 n (%)
Frequency
2n = 213
Codons 10 and 25 CTCG TG ⁄TG 8 (1.8) 0.019 46 (21.6) 0.216 <0.0001 High producer
CG ⁄TG 156 (36.71) 0.367 35 (16.43) 0.164 0.004
CC ⁄TG 0 0 19 (8.92) 0.089 <0.0001 Intermediate producer
CG ⁄CG 123 (28.94) 0.289 17 (7.98) 0.08 <0.0001
TG ⁄TC 20 (4.71) 0.047 7 (3.29) 0.033 NS
CG ⁄CC 41 (9.65) 0.096 40 (18.78) 0.188 0.01 Low producer
CC ⁄CC 57 (13.41) 0.134 5 (2.35) 0.024 <0.0001
TC ⁄TC 0 – 35 (16.43) 0.164 <0.0001
TC ⁄CC 20 (4.71) 0.047 9 (4.22) 0.042 NS
aThe first and second characters of each two bases indicate the bases at positions +869 (codon 10) and +915 (codon 25), respectively, of the signal sequence of the TGF-b1 gene.
NS, not significant.
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Overall, the C allele at position +869 and the G
allele at position +915 in the first exon of the TGF-
b1 gene were more common among patients than
among controls, while the mutant T allele at
codon 10 was less frequent among patients than
among controls. Previous studies have shown a
correlation between the two polymorphisms and
the concentration of TGF-b1 in human serum
[6,7]. The present findings indicate that these
polymorphisms may be involved in modulating
the expression of the TGF-b1 gene, and that
particular alleles may therefore be predisposing
factors for brucellosis. As shown in Table 1, the
homozygous genotype CC, at either codon 10 or
codon 25, is associated strongly with low produc-
tion, while the homozygous genotype GG at
codon 25 is associated with high production.
When the GG and CC genotypes are present
together, intermediate production is observed,
indicating an interaction, or dose effect, of the two
alleles.
The increased frequency of the TGF-b1 high-
producer genotype among brucellosis patients
suggests that the suppression of immune status
by TGF-b1 [8,9] in the high-producer genotype is
more pronounced, and that this dose-dependent
modulation influences the overall susceptibility to
the infecting organisms. The results of this study
revealed that the codon 10 CC wild-type geno-
type and the codon 25 GG mutant genotype could
be potential risk-factors for brucellosis, while the
TGF-b1 codon 10 T ⁄T mutant genotype might be
a possible protective factor. The Leu10 and Pro25
allele was associated with an increased risk of
myocardial infarction [10,11]. Many pathogens
have immune-subversion strategies, e.g., increas-
ing anti-inflammatory or immunosuppressive
responses. This can be achieved directly by
induction of host immunosuppressive cytokines,
e.g., interleukin-10 and TGF-b1, which are
produced by innate immune cells in response
to pathogen-derived molecules [12,13], or indi-
rectly through the generation of regulatory
T-cells.
TGF-b1 has been reported previously to inhibit
many T-cell functions, including the proliferation
and development of cytotoxic T-cells and T-
helper cells of types 1 and 2 [14,15], but TGF-b1-
secreting regulatory T-cells can be both beneficial
and detrimental to the host in response to the
same pathogen. As shown in Table 2, the homo-
zygous genotype CC, either at codon 10 or at
codon 25, is associated strongly with low TGF-b1
production. TGF-b1 haplotypes CG ⁄TG, CG ⁄CG
and CC ⁄CC were significantly more frequent
among patients with brucellosis than among
controls, whereas TGF-b1 haplotype TG ⁄TG was
significantly less frequent among patients with
brucellosis. Haplotypes CG ⁄TG and CG ⁄CG are
associated with high and intermediate TGF-b1
production, respectively [6,16].
In conclusion, polymorphisms at codons 10 and
25 of TGF-b1, and their haplotypes, were associ-
ated significantly with the risk of brucellosis.
These results suggest that the TGF-b1 gene may
contribute to an inherited predisposition to bru-
cellosis.
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A B S T R A C T
Meningococcal invasive disease is a life-threaten-
ing infection that affects mostly children and
adolescents. The present study was performed
during 2003–2005 to compare the phenotypic
characteristics of meningococcal isolates from
these two main groups at risk with those of
isolates from other age groups to assess whether
strategies for treatment and prevention imple-
mented elsewhere can also be applied in Italy.
The results showed that serogroup C meningo-
cocci were predominant, and that a dramatic
increase in the circulation of strains with de-
creased susceptibility to penicillin was associated
mainly with a prevalent phenotype C:2b:P1.5,2,
which belongs to the hyper-virulent ST8 ⁄A4
cluster.
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Children in the first few years of life and adoles-
cents are the two age groups most at risk of
developing invasive meningococcal disease. De-
spite the availability of a targeted therapy, the
disease remains life-threatening, and many efforts
have been made in recent years to design safe
immunogenic vaccines. Currently, polysaccharide
and conjugate vaccines can prevent cases caused
by Neiserria meningitidis serogroups A, C, Y and
W135, and serogroup C only, respectively [1,2]. In
addition, the newer outer-membrane vesicle
(OMV) vaccines, which contain the meningococ-
cal outer-membrane proteins (PorA) of class 1 that
are normally used for strain subtyping [3], seem
to be able to overcome the disadvantages of
immunogenicity and cross-reactivity with host
tissue that occur with the meningococcal B poly-
saccharide [4]. The main constraint in the devel-
opment of OMV vaccines is the great diversity of
sero-subtypes circulating in different geograph-
ical areas, which would require ad-hoc vaccine
production tailored to each specific situation [5,6].
Meningococci with decreased susceptibility to
penicillin (PenI) have been described since the
mid-1980s [7], and their frequency is increasing
constantly throughout the world. Although fully-
resistant strains have not yet been isolated in
Italy, the situation requires constant monitoring.
The aim of the present work was to assess the
meningococcal phenotypes circulating during
2003–2005 in Italy in the two groups most at risk,
i.e., children aged £4 years and adolescents aged
15–19 years, since different opportunities are
available for prophylaxis and it is imperative
for national public health laboratories to have
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